FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Correlating Device Inspections with Warning Letters

Attorney Bradley Thompson uses data analysis to determine medical device inspection observations that more frequently are associated with Warning Lett...

Federal Register

Anesthetic/Analgesic Drugs Panel Renewal

Federal Register notice: FDA announces its renewal of the Anesthetic and Analgesic Drug Products Advisory Committee for an additional two years beyond...

Federal Register

Guide on Circulating Tumor DNA Drug Development

Federal Register notice: FDA makes available a draft guidance entitled Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development.

Human Drugs

More Transparency in Advisory Committee Use Needed: Researchers

Harvard University researchers who looked at FDAs use of advisory committees for new drugs say reforms in the process would improve transparency and a...

Human Drugs

Paxlovid Widely Available in Pharmacies: Farley

CDER Office of Infectious Diseases director John Farley answers healthcare provider questions about using Pfizers Paxlovid on authorized Covid-19 pati...

Medical Devices

FDA OKs Marketing of New Alzheimers Diagnostic

FDA permits marketing of a Fujirebio in vitro diagnostic test for Alzheimers disease.

Marketing

Additional FDA Native Advertising Enforcement Likely: Attorney

Attorney Dara Levy predicts increased FDA enforcement involving so-called native advertising and other new promotional trends.

Human Drugs

ICH Model-Informed Drug Development Roadmap

The International Council on Harmonization publishes its Model-Informed Drug Development Discussion Group roadmap for future guidelines.

FDA General

User Fee Bill Looks to Improve Accelerated Approval, Inspections

The House Energy and Commerce Committee releases a comprehensive legislative package to reauthorize FDA user fee agreements and enhance accelerated ap...

Medical Devices

Revised Guide on PMA/HDE Supplements During Covid

FDA posts a revised final guidance entitled Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions Durin...